{
    "clinical_study": {
        "@rank": "6758", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if valacyclovir affects the detection of HIV in genital\n      herpes lesions in HIV-infected patients. Valacyclovir is used to treat recurrent genital\n      herpes."
        }, 
        "brief_title": "The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients", 
        "condition": [
            "Herpes Simplex", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Herpes Simplex"
            ]
        }, 
        "detailed_description": {
            "textblock": "Following evaluation for 2 consecutive episodes of genital herpes in this double-blind,\n      crossover study, 30 HIV-1 positive patients are randomized to receive either valacyclovir or\n      placebo.\n\n      All patients are treated for 10 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Serologically documented HSV-2 and HIV-1 infection.\n\n          -  History of recurrent genital herpes that presents at least 3 recurrences within the\n             12 months prior to the start of study.\n\n          -  No contraindications to valacyclovir.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          1. Hepatic impairment.\n\n          2. Impaired renal function (creatinine above 2 mg/dl).\n\n          3. Malabsorption syndrome or other gastrointestinal dysfunction.\n\n          4. Any other condition that in the investigator's opinion would interfere with study\n             procedures or successful completion of protocol.\n\n        Patients with the following prior conditions are excluded:\n\n        History of hypersensitivity to acyclovir or valacyclovir.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Participation in any investigational drug trial within 1 month prior to entry on\n             study.\n\n          -  Systemic anti-HSV therapy within 7 days prior to start of study drug.\n\n             1. Probenecid.\n\n          -  Suppressive treatment with medication that has anti-HSV activity.\n\n        Required:\n\n        - Stable antiretroviral therapy or no therapy for at least 1 month."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002404", 
            "org_study_id": "291A"
        }, 
        "intervention": {
            "intervention_name": "Valacyclovir hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Valacyclovir", 
                "Acyclovir"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Antiviral Agents", 
            "Herpes Genitalis", 
            "Recurrence", 
            "DNA, Viral", 
            "RNA, Viral", 
            "valacyclovir", 
            "Herpesvirus 2, Human"
        ], 
        "lastchanged_date": "January 24, 2008", 
        "official_title": "The Effect of Treatment With Valacyclovir 500 mg BID on the Detection of HIV From Genital HSV Lesions in HIV-Infected Patients: A Double-Blind Crossover Study", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002404"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1999"
    }, 
    "geocoordinates": {}
}